Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 14 of 14

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Log Transformed Binge Days Per Week at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	Log days	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks	Baseline and up to 11 weeks	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	Binge Episodes	MEAN
SECONDARY	1-Week Binge Response, Last Observation Carried Forward (LOCF)	Last 7 days on study	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	Participants	NUMBER
SECONDARY	4-Week Binge Response	Last 28 days on study	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	Participants	NUMBER
SECONDARY	Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline	Baseline	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment. (Not all subjects in the FAS had an assessment for this outcome.)	Percentage of participants	NUMBER
SECONDARY	Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks	up to 11 weeks	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment. (Not all subjects in the FAS had an assessment for this outcome.)	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks	Up to 11 weeks	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment. (Not all subjects in the FAS had an assessment for this outcome.)	Percentage of participants	NUMBER
SECONDARY	Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Eating Inventory Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Binge Eating Scale (BES) Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11	Baseline and week 11	Full Analysis Set defined as all subjects who had taken at least 1 dose of investigational product and who had 1 post-baseline primary efficacy assessment.	units on a scale	LEAST_SQUARES_MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01291173/outcomes

API reference For AI assistants